A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung — LCNEC-ALPINE

Large Cell Neuroendocrine Carcinoma of the Lung Clinical Trial

Official title:
A Phase II, Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Status Recruiting

Clinical Trial Summary

This phase II clinical trial evaluates the efficacy, safety and tolerability of Atezolizumab in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Neuroendocrine
Large Cell Neuroendocrine Carcinoma of the Lung
Lung Neoplasms

Clinical Trial Details

NCT number	NCT05470595
Study type	Interventional
Source	Technische Universität Dresden
Contact	Martin Wermke, MD
Phone	+49 351 7566
Email	martin.wermke@ukdd.de
Status	Recruiting
Phase	Phase 2
Start date	January 18, 2022
Completion date	January 31, 2029

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03901378` - Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma	Phase 2
Not yet recruiting	`NCT06393816` - FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum	Phase 2
Completed	`NCT06049966` - Atezolizumab in Large Cell Neuroendocrine Carcinoma	Phase 1
Recruiting	`NCT05680922` - DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer	Phase 1
Recruiting	`NCT04010357` - Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC	Phase 2
Recruiting	`NCT02755675` - uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung	Phase 2